Please login to the form below

Not currently logged in
Email:
Password:

finerenone

This page shows the latest finerenone news and features for those working in and with pharma, biotech and healthcare.

Xarelto and Eylea continue to dominate Bayer's pharma sales

Xarelto and Eylea continue to dominate Bayer's pharma sales

They include five candidates in phase III trials: copanlisib for non-Hodgkin lymphoma, ODM-201 for hormone-sensitive prostate cancer, finerenone for diabetic kidney disease, vilaprisan for uterine fibroids and endriametosis

Latest news

More from news
Approximately 1 fully matching, plus 4 partially matching documents found.

Latest Intelligence

  • Heart failure therapy embarks on a new era Heart failure therapy embarks on a new era

    Bayer recently started three late-stage trials of its HF candidate finerenone - a mineralocorticoid drug designed as a safer replacement for older drugs in the class such as eplerenone and spironolactone,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
M&F Health

M&F Health is a full service communications agency, dedicated to the health and wellbeing sector. We are an independent amongst...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics